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 TAT protein expression in the brain facilitates reversal learning in mice. 
 TAT expression tended to increase the conversion of glutamate to glutamine. 
 MAO inhibitor selegiline decreased the metabolism of dopamine and serotonin. 
 Chronic selegiline treatment increased glutamate levels in the caudate putamen. 
 Chronic selegiline treatment does not alter spatial memory or reversal learning. 
 Abstract 
Neurotoxic viral protein TAT may contribute to deficits in dopaminergic and cognitive 
function in individuals infected with human immunodeficiency virus. Transgenic mice with 
brain-specific doxycycline-induced TAT expression (TAT+, TAT- control) show impaired 
cognition. However, previously reported TAT-induced deficits in reversal learning may be 
compromised by initial learning deficits. We investigated the effects of TAT expression on 
memory retention/recall and reversal learning, and neurotransmitter function. We also 
investigated if TAT-induced effects can be reversed by improving dopamine function with 
selegiline, a monoamine oxidase inhibitor. Mice were tested in the Barnes maze and TAT 
expression was induced after the task acquisition. Selegiline treatment continued throughout 
behavioral testing. Dopamine, serotonin and glutamate tissue levels in the 
prefrontal/orbitofrontal cortex, hippocampus and caudate putamen were measured using high 
performance liquid chromatography. Neither TAT expression nor selegiline altered memory 
retention. On day 2 of reversal learning testing, TAT+ mice made fewer errors and used more 
efficient search strategies than TAT- mice. TAT expression decreased dopamine turnover in 
the caudate putamen, increased serotonin turnover in the hippocampus and tended to increase 
the conversion of glutamate to glutamine in all regions. Selegiline decreased dopamine and 
serotonin metabolism in all regions and increased glutamate levels in the caudate putamen. In 
the absence of impaired learning, TAT expression does not impair spatial memory 
retention/recall, and actually facilitates reversal learning. Selegiline-induced increases in 
dopamine metabolism did not affect cognitive function. These findings suggest that TAT-
induced alterations in glutamate signaling, but not alterations in monoamine metabolism, may 
underlie the facilitation of reversal learning. 
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 Abbreviations 
3-MT: 3-methoxytyramine 
5-HIAA: 5-hydroxy-indoleacetic acid 
5-HT: serotonin 
AIDS: acquired immunodeficiency syndrome 
ANOVA: analysis of variance 
CPu: caudate putamen 
DA: dopamine 
DOPAC: dihydroxyphenylacetic acid 
GABA: γ-aminobutyric acid 
GFAP: glial fibrillary acidic protein 
Gln: glutamine 
GLU: glutamate 
HAD: HIV associated dementia 
HIV: human immunodeficiency virus 
HPLC: high performance liquid chromatography 
HVA: homovanillic acid 
LSD: least significant difference 
MAO: monoamine oxidase 
ORB: orbitofrontal cortex 
PFC: prefrontal cortex 
Ret: retention 
Rv: reversal learning 
Sel: selegiline 
SEM: standard error of the mean 
SIV: simian immunodeficiency virus 
SME: significant main effects 
WM: working memory. 
 1. Introduction 
Mild neuropsychological impairments associated with Human Immunodeficiency 
Virus (HIV) infection are relatively common, occurring in approximately 50% of people with 
AIDS [1] receiving combination antiretroviral therapy [2]. HIV-related brain dysfunction is 
associated with frontal-subcortical mediated patterns of cognitive deficits, characterized by 
impairments in working memory, processing speed, executive function, learning and motor 
skills [1, 3, 4]. This collection of symptoms suggest the brain regions most commonly 
damaged in HAD are the basal ganglia, hippocampus, and cerebral cortex [5]. Due to the 
persistence of cognitive deficits in HIV patients, identifying neurobiological mechanisms and 
subsequently, therapeutics for HIV-related cognitive deficits is a growing area of interest in 
the field of HIV research [3].  
HIV-induced neurodegeneration involves, in part, HIV viral products including the non-
structural protein TAT which plays a central role in the pathogenesis of the HIV infection (for 
review, [6]) and may contribute to cognitive deficits in treated patients. For example, the TAT 
protein has been found in the post-mortem brain tissue of patients with HIV [7, 8]. 
Transgenic mice that express the viral TAT protein under the glial fibrillary acidic protein 
(GFAP) promoter provide a useful in vivo model to study the impact of TAT protein in 
cognitive function. TAT-induced mice show neuropathology similar to that observed in HIV-
infected humans including apoptosis, astrocytosis, neurodegeneration of the cortex, 
degeneration of dendrites, inflammation and premature death [9]. TAT protein also induces 
dysfunction of dopaminergic neurotransmission in corticolimbic brain circuits [10-13] that are 
involved in memory and executive function [14-16]. TAT expression in mice leads to impaired 
learning, memory and cognitive flexibility (reversal learning) [17, 18]. However, an 
important caveat to these studies is that TAT expression was induced prior to the task 
acquisition. Therefore, deficits in learning may compromise the subsequent testing of 
memory retrieval and reversal learning. Thus, it is important to design experiments that can 
discretely assess memory and reversal learning independent of concomitant impairments in 
learning after TAT expression. 
HIV infection has been shown to preferentially target the basal ganglia, leading to 
decreased caudate/basal ganglia volume [19, 20]. Both caudate atrophy and decreased 
dopamine levels have been associated with impaired cognitive performance in HIV-infected 
humans [20-22]. TAT infusions into the striatum resulted in decreased levels of potassium-
evoked dopamine release 24 and 48 h later [10] and TAT has been shown, in vitro, to induce 
rapid and reversible effects on dopamine uptake and storage [12, 13]. Dopamine function in 
the prefrontal cortex (PFC) and caudate putamen (CPu) of rodents has been associated with 
memory retrieval and reversal learning [23, 24]. Furthermore, interactions with dopamine 
systems via other brain regions such as the orbitofrontal cortex (ORB)[25] and hippocampus 
[26] are also important for both memory and adaptive responses. Selegiline, a monoamine 
oxidase (MAO) inhibitor, decreases dopamine and serotonin (5-HT) metabolism [27], in 
addition to having antioxidant and neuroprotective functions [28]. Selegiline treatment 
improved age-related memory deficits in rodents [29] as well as memory deficits induced by 
a variety of insults in rodent models [30-32]. Moreover, selegiline treatment in monkeys with 
SIV has improved dopamine-related function in the brain [33]. Based on these findings, we 
hypothesized that selegiline may be promising treatment for TAT-induced memory 
impairments by improving brain dopamine function with possible downstream effects on 
glutamate and γ-aminobutyric acid (GABA) systems.  
The goal of the present study was to determine the impact of TAT expression and 
chronic selegiline treatment on memory retention, reversal learning and neurotransmitter 
function. To discretely assess memory and reversal learning without confounding alterations 
in learning, mice were trained to learn the location of the escape tunnel in the Barnes maze 
test prior to TAT expression or selegiline treatment. Subsequently, the effects of TAT 
expression, with and without selegiline, on memory retention/recall and reversal learning were 
assessed. Dopamine, 5-HT, glutamate and GABA function in regions associated with memory 
and reversal learning including the PFC, ORB, CPu and hippocampus was determined using 
high performance liquid chromatography (HPLC). 
 
2. Materials and methods 
2.1 Animals 
 A total of 60 male mice all containing the GFAP-null alleles but only half containing 
the TAT protein transgene were used in this study. Inducible TAT transgenic mouse colonies 
with a C57BL/6J background were obtained by generation of two separate transgenic lines 
Teton-GFAP mice and TRE-Tat86 mice, and then cross-breeding of these two lines of 
transgenic mice as previously described [9]. The mice were housed in groups of 2-4 in a 
humidity- and temperature-controlled animal facility on a 12 h/12 h reverse light/dark cycle 
(lights off at 7:00 AM) with ad libitum access to food and water. Behavioral testing was 
conducted during the dark phase of the light/dark cycle. All of the experiments were 
conducted in accordance with the guidelines of the American Association for the 
Accreditation of Laboratory Animal Care and National Research Council’s Guide for the 
Care and Use of Laboratory Animals and approved by the University of California San Diego 
Institutional Animal Care and Use Committee. 
 
2.2 Experimental Design 
 A graphical representation of the experimental design is presented in Figure 1. TAT- 
(n=30) and TAT+ (n=30) mice were trained to learn the spatial location of the escape tunnel 
during the acquisition trials followed by the probe test in the Barnes maze. Subsequently, 
TAT+ and TAT- mice were divided into two equally performing groups based on latency, 
strategy and reference errors during the final three days of acquisition trials. Then all mice 
were treated with a doxycycline hyclate regimen (100 mg/kg, Sigma, St. Louis, MO, USA) 
consisting of intraperitoneal injections once a day for 7 days at 08:00 and starting two days 
after the probe test. This doxycycline regimen is based on the previously demonstrated 
efficacy of TAT induction at this dose of doxycycline [9, 17]. Selegiline hydrochloride (Sel+; 
Sigma), 2 mg/kg subcutaneously once per day at 17:00 [29], or saline (Sel-) treatment began 
two days after the first doxycycline administration and continued throughout behavioral 
testing. The final number of mice included in each test group were as follows: TAT-/Sel- 
n=16, TAT+/Sel- n=16, TAT-/Sel+ n=13 and TAT+/Sel+ n=15. Effects of TAT and 
selegiline on memory retention were assessed 15-days after the completion of acquisition 
trials and followed immediately with reversal trials. Brain samples were taken the day 
following the final reversal trials. 
 
2.3 Barnes maze test 
 The Barnes maze testing was conducted similar to that described previously [34, 35]. 
The maze consisted of a white, acrylic, circular disc (90 cm diameter) that was elevated 90 
cm above the floor, with 20 equally spaced holes (San Diego Instruments, San Diego, CA) 
with a black acrylic escape box (20  5  6 cm) placed under one of the holes. The maze was 
surrounded by four spatial cues at the height of the maze. Illumination in the center of the 
maze was approximately 900 lux. The maze was rotated 90 degrees each day to avoid the use 
of local cues on the maze by the mice. 
 
2.3.1 Acquisition trials 
 Each mouse underwent 20 acquisition trials over 5 days, tested four times a day with 
an intertrial interval of 10-15 min. Immediately prior to the first trial, all of the mice were 
individually placed into the escape tunnel for 1 min to avoid any neophobic responses. 
During testing, the mice were placed into a starting cylinder (10 cm diameter) in the center of 
the maze for 30 s. The cylinder was then removed, and the mouse was allowed to explore the 
arena to find the escape tunnel. The trial ended when the mouse entered the escape tunnel 
(i.e., when all four paws left the maze). When the mouse entered the escape tunnel, the entry 
was blocked, and the mouse was left in the tunnel for 1 min. If the mouse did not find or enter 
the escape tunnel within 3 min, then it was manually placed into the escape tunnel. 
 
2.3.2 Probe trial 
 The 3-min probe trial was conducted on day 6 and was identical to the acquisition 
trials, with the exception that the escape tunnel was removed.  
 
2.3.3 Memory retention 
 Two weeks after the probe test, the mice were tested for memory retention over four 
trials identical to the acquisition trials. 
 
2.3.4 Reversal learning 
 For two days after the memory retention trials mice were tested for reversal learning. 
Each day consisted of four trials identical to the acquisition trials, but the location of the 
escape tunnel for each mouse was shifted 180.  
 
2.3.5 Behavioral measures 
 All behaviors were scored from video files by an experimenter who was blind to the 
experimental conditions. The measures assessed were the latency to find the target hole, 
number of reference errors, number of working memory errors, and number of perseverative 
errors. Reference errors were defined as any incorrect hole inspection. Working memory 
errors were defined as searching the same hole twice within a trial when the revisit occurred 
after the inspection of other holes. Perseverative errors were defined as repeated searches of 
the same hole without searching another hole in between. Search strategy was also assessed 
in the acquisition, retention, and reversal trials. The search strategy was defined as one of 
three categories: spatial, serial, and random/mixed [34, 35]. A spatial strategy was defined as 
finding the target hole directly or after inspecting one of the adjacent holes first (≤ one 
reference error). Random/mixed (<74%) and serial (≥75%) strategy scores were defined 
based on the percentage of reference errors that were made in a serial fashion. For an error to 
be defined as serial, this error had to be part of a minimum of three consecutive errors made 
in either direction around the maze without skipping a hole or changing direction. The 
percentages of each strategy used during the 4 daily trials were calculated. In the probe trial, 
the time spent by each mouse in the quadrant of the maze that contained the target hole was 
calculated. 
 
2.4 High performance liquid chromatography and analysis 
Catecholamines and amino acids from brain tissue were measured by HPLC with 
electrochemical detection for catecholamines and fluorescence detection for amino acids [36, 
37]. Brain tissues were homogenized in 0.1 M perchloric acid with 50 ng/mL 
deoxyepinephrine (catecholamine internal standard) using probe sonication (Vibra-Cell, 
Sonics & Materials, CT, USA) and centrifuged at 13,000 rpm for 5 min. The supernatant was 
filtered by a 4 mm 0.22 µM nylon syringe filter (MicroSolv Technology Corporation, NJ, 
USA). For catecholamines, 15 µL of sample was injected into the HPLC system, which 
consisted of an autosampler (Dionex UltiMate 3000, Thermo Scientific, CA, USA), an 
isocratic HPLC pump (Model 584, ESA Laboratories, MA, USA), a Sunfire C18 column, 
(4.6 mm × 100 mm, 3 um; Waters Corporation, MA, USA) and a Coulochem III (ESA 
Laboratories) electrochemical detector. The mobile phase consisted of a 12% acetonitrile/50 
mM citric acid and 25 mM potassium dihydrogen phosphate buffer containing 1 mM EDTA 
and 1.4 mM octane sulfonic acid adjusted to pH 4.3 with phosphoric acid. Flow rate was 0.5 
ml/min. An analytical cell (Model 5014B, ESA Laboratories) with the first and second 
electrodes maintained at –150 and +300 mV, respectively, was used for detection. Amino 
acids were analyzed using pre-column derivatization at 4◦C and fluorescence detection. The 
derivatisation protocol was conducted by the autosampler as follows: 10 µL of 1 nM/µL 
homoserine (amino acid internal standard) was mixed with 10 µL of sample; then 20 µL of 
borate buffer (0.4 M at pH 10) was added and mixed; then 5 µL of OPA reagent (100 mg o-
phthalaldehyde in 1 ml methanol with 9 ml borate buffer and 50 µl mercaptoethanol) was 
added and mixed; then after a 30 sec wait, 50 µL of mobile phase was added and mixed; 5 µl 
of the final solution was injected into the HPLC system. The system consisted of an isocratic 
pump and autosampler (Dionex UltiMate 3000, Thermo Scientific), and fluorescence detector 
(Model 2475, Waters Corporation) equipped with a Phenomenex Gemini C18 column (4.6 
mm × 150 mm, 3 um; Phenomenex, CA, USA). The mobile phase consisted of 0.05 M 
sodium acetate, tetrahydrofuran and acetonitrile (74:1:25, v/v) adjusted to pH 4.0 using 100% 
acetic acid. Flow rate was 1 ml/min and the fluorescence detector was set to an excitation 
wavelength of 337 nm and an emission wavelength of 454 nm. All data was stored and 
processed with Dionex Chromeleon software (version 7.2, Thermo Scientific). Data was 
quantified by calculating peak-area ratios of each compound compared to the relevant 
internal standard and expressed as pg/mg (catecholamines) or ng/mg (amino acids) of tissue. 
 
2.5 Statistical analyses 
 All of the analyses were performed with IBM SPSS Statistics 20 (Armonk, NY, 
USA). All neurochecmical and behavioral data were analyzed using analysis of variance 
(ANOVA), with TAT and Selegiline as the between-subject factors. For Barnes maze 
acquisition data repeated-measures ANOVAs were used with Day and Trial as the repeated 
measures. For Barnes maze retention and reversal learning data repeated-measures ANOVAs 
were used with Trial as the repeated measure. When appropriate, post hoc comparisons were 
performed using Least Significant Difference (LSD) test. Results are expressed as mean ± 




3.1 Barnes maze acquisition 
All mice learnt to find the escae tunnel during the acquisition phase. The final 3 days 
of acquisition were used to balance groups for subsequent selegiline treatment. There were no 
differences between experimental groups in the relevant outcome measures including 
reference errors, working memory errors, perseverative errors and search strategies during the 
final three days of acquisition trials (Supplementary Figure 1). There were also no differences 
between experimental groups in the time spent in the target quadrant during the probe trial 
(Supplementary Figure 2). In all cases there were no significant main effects of TAT or 
Selegiline, and no significant interactions of TAT x Selegiline. The lack of any observable 
deficits in performance prior to TAT induction support other studies demonstrating that 
transgene leakage in this model is small or negligible [38]. 
 
3.2 Memory retention 
There was no effect of TAT or Selegiline on behavioral measures of memory retention 
(Figure 2). All mice maintained memory of the escape tunnel location as demonstrated by no 
significant differences between the retention trials and the last day of acquisition trials in any 
measure.  
 
3.3 Reversal learning 
Neither Gene nor Selegiline led to any significant effects on latency, errors or strategy 
use on the first day of reversal learning (Figure 2). All mice improved performance across 
the four trials as demonstrated by significant main effects of Trial on latency (F3,168 = 32.2, p 
< 0.001), reference errors (F3,168 = 38.2, p < 0.001), working memory errors (F3,168 = 34.4, p 
< 0.001) and perseverative errors (F3,168 = 19.7, p < 0.001). On the second day of reversal 
learning there were significant main effects of TAT on latency (F1,56 = 4.9, p < 0.05), 
reference errors (F1,56 = 11.2, p < 0.001) and working memory errors (F1,56 = 9.9, p < 0.01). 
To find the escape tunnel, TAT+ mice took less time (Figure 3A), and made less reference 
(Figure 3B) and working memory (Figure 3C) errors compared with control mice. There 
was also a near significant interaction of TAT x Selegiline on the spatial strategy use for the 
second day of reversal learning (F1,56 = 3.9, p = 0.053) with TAT+/Sel- mice using a spatial 




3.4.1 Caudate putamen 
In the CPu (Table 1), chronic selegiline treatment significantly increased levels of 
dopamine (F1,54 = 32.7, p < 0.001) and 3-methoxytyramine (3-MT; F1,54 = 70.6, p < 0.001), 
but decreased levels of dihydroxyphenylacetic acid (DOPAC; F1,54 = 147.3, p < 0.001) and 
homovanillic acid (HVA; F1,54 = 12.2, p < 0.001). Decreased dopamine turnover in response 
to selegiline treatment was demonstrated by significant decreases in the ratio of 
HVA/dopamine (F1,54 = 102.7, p < 0.001), DOPAC/dopamine (F1,54 = 180.9, p < 0.001) and 
DOPAC/HVA (F1,54 = 106.4, p < 0.001). Significant increases in both 5-HT (F1,54 = 5.7, p < 
0.05) and glutamate (F1,54 = 5.4, p < 0.05) were also observed. 
TAT expression decreased levels of DOPAC (F1,54 = 5.9, p < 0.05) and decreased the 
ratios of DOPAC/dopamine (F1,54 = 6.0, p < 0.05) and DOPAC/HVA (F1,54 = 5.3, p < 0.05). 
A significant interaction of TAT x Selegiline was observed for the DOPAC/dopamine ratio 
(F1,54 = 4.0, p < 0.05) with TAT+/Sel- mice having a significantly lower ratio when compared 
with TAT-/Sel- mice (p < 0.01). In addition, there were trends for increased levels of 
glutamine (F1,54 = 3.1, p = 0.086) and an increased glutamine/glutamate ratio (F1,54 = 3.4, p = 
0.069) after TAT expression. 
 
3.4.2 Hippocampus 
In the hippocampus (Table 2), chronic selegiline treatment significantly increased 
levels of dopamine (F1,56 = 21.5, p < 0.001) and 3-MT (F1,56 = 13.3, p < 0.001) but decreased 
levels of DOPAC (F1,56 = 63.3, p < 0.001) and HVA (F1,56 = 9.5, p < 0.01). Decreased 
dopamine turnover in response to selegiline treatment was also demonstrated by significant 
decreases in the ratio of HVA/dopamine (F1,56 = 58.3, p < 0.001), DOPAC/dopamine (F1,56 = 
104.4, p < 0.001) and DOPAC/HVA (F1,56 = 67.6, p < 0.001). Selegiline treatment also 
significant impacted the 5-HT system with increased levels of 5-HT (F1,56 = 31.2, p < 0.001), 
decreased levels of 5-hydroxy-indoleacetic acid (5-HIAA; F1,56 = 16.3, p < 0.001) and a 
decreased ratio of 5-HIAA/5-HT (F1,56 = 30.6, p < 0.001) were observed. 
TAT expression lead to increased turnover of 5-HT as demonstrated by increased 
levels of the metabolite 5-HIAA (F1,56 = 4.0, p < 0.05). In addition, there were trends towards 
increased levels of glutamine (F1,56 = 3.2, p = 0.081) and an increased glutamine/glutamate 
ratio (F1,54 = 3.6, p = 0.062) after TAT expression. A significant interaction of TAT x 
Selegiline was also observed for GABA levels (F1,56 = 5.6, p < 0.05) with trends toward the 
TAT-/Sel+ mice having lower GABA levels compared with both TAT-/Sel- mice (p < 0.086) 
and TAT+/Sel+ mice (p < 0.076). 
 
3.4.3 Prefrontal cortex 
In the PFC (Table 3), chronic selegiline treatment significantly increased levels of 
dopamine (F1,56 = 6.3, p < 0.05) and 3-MT (F1,56 = 9.0, p < 0.01) but decreased levels of 
DOPAC (F1,56 = 7.2, p < 0.05). Decreased dopamine turnover in response to selegiline 
treatment was also demonstrated by significant decreases in the ratio of HVA/dopamine (F1,56 
= 12.0, p < 0.001) and DOPAC/dopamine (F1,56 = 24.0, p < 0.001). Selegiline treatment also 
significant impacted the 5-HT system with significantly increased levels of 5-HT (F1,56 = 
10.6, p < 0.01) and a trend for a decreased ratio of 5-HIAA/5-HT (F1,56 = 30.6, p = 0.057) 
observed. 
TAT expression did not alter dopamine or 5-HT systems but trends for increased 
levels of glutamine (F1,56 = 3.3, p = 0.075) and an increased glutamine/glutamate ratio (F1,56 
= 3.8, p = 0.056) were observed. 
 
3.4.4 Orbitofrontal cortex 
In the ORB (Table 4), chronic selegiline treatment tended to increase levels of 
dopamine (F1,56 = 3.5, p = 0.065), but significantly increased levels of 3-MT (F1,56 = 22.1, p < 
0.001) and decreased levels of DOPAC (F1,56 = 8.9, p < 0.01). Furthermore, decreased 
dopamine turnover in response to selegiline treatment was also demonstrated by significant 
decreases in the ratio of HVA/dopamine (F1,56 = 5.9, p < 0.05) and DOPAC/dopamine (F1,56 
= 12.3, p < 0.001). Selegiline treatment also significant impacted the 5-HT system with 
significantly increased levels of 5-HT (F1,56 = 12.1, p < 0.001) and a decreased ratio of 5-
HIAA/5-HT (F1,56 = 5.7, p < 0.05) observed. 
TAT expression did not alter dopamine or 5-HT systems but a trend for an increased 
glutamine/glutamate ratio (F1,54 = 2,.8, p = 0.097) was observed. 
4. Discussion 
The main findings of this study are that TAT expression in mice, when induced after 
task acquisition, did not affect memory retention/recall but facilitated reversal learning on the 
second day of testing. Even though prior work has demonstrated reversal learning deficits in 
TAT-expressing mice [17], TAT expression was induced before the acquisition of the 
behavioral tasks and led to impaired learning during the task acquisition [17]. Thus, it would 
appear that previously observed deficits in memory and reversal learning may be a 
consequence of impairments in the initial learning rather than reversal learning deficits per 
se. Further, although chronic selegiline treatment significantly altered dopamine and 5-HT 
systems throughout the brain, it did not affect memory retention and had subtle effects on 
reversal learning. These results suggest that chronic selegiline treatment does not 
significantly impact spatial reversal learning in the absence of learning impairments. 
 
4.1 Effects of TAT protein on memory retention/recall 
In contrast to our hypothesis, prior TAT expression did not impair memory 
retention/recall but, in fact facilitated reversal learning. Given that TAT expression is likely 
to have substantially decreased or even ceased by the time of memory retention/recall testing 
[38], it is still likely that deficits may be observed during periods of active TAT expression. 
However, the present results suggest that there are no persisting effects of TAT expression on 
these outcome measures. TAT-induced deficits in spatial learning and memory have been 
observed in mice using both the Barnes maze [17] and the Morris water maze [18], but in 
both studies TAT-expression was induced prior to or throughout testing. Thus, it would 
appear that spatial memory retention/recall is not negatively affected by prior TAT 
expression in mice.  Memory impairments have been observed in rats given intra-
hippocampal TAT protein infusion after task acquisition in the Morris water maze [39] 
suggesting that a greater level of TAT protein may be required to induce memory 
impairments. Alternatively, the training used prior to TAT protein infusion featured 
significantly less training trials compared with the current study. A strong bias toward the 
target quadrant in the probe trial provides clear evidence that mice in the current protocol 
were using spatial cues to determine the escape tunnel position. Moreover, the low number of 
reference errors made on day 5 of acquisition (approximately 2.5) was less than would be 
made by using a serial strategy without any spatial cues (e.g., approximately 9.5 if randomly 
choosing a starting hole and turning left or right 50% of the time). Thus, the effects of TAT 
exposure on memory recall may depend on the strength of the memory i.e. weaker memories 
in less trained mice are more susceptible to TAT-induced impairments.   
 
4.2 Effects of TAT protein on reversal learning 
TAT expression facilitated reversal learning on Day 2 but not Day 1 suggesting that 
prior TAT exposure may affect reversal learning in a phase-dependent manner. For example, 
reversal learning features an initial phase whereby errors are mainly due to the previously 
learnt association; while a late phase is driven by the learning of the new association [40]. 
Paradoxically, lesions of the ventromedial PFC in mice facilitated late-stage reversal learning 
in an operant visual reversal learning task [40]. HIV disease has been shown to decrease 
cortical gray matter, which has been associated with neurocognitive impairments [41], 
decrease PFC activity during neurocognitive tasks [42] and induce frontocortical astrocytosis 
[43]. Similarly, TAT expression in mice resulted in cortical astrocytosis and degeneration of 
neuronal dendrites [9] suggesting that PFC neuropathology after TAT expression may 
underlie the observed reversal learning facilitation. Such impairments in PFC function may 
facilitate reversal learning by disinhibition of subcortical areas involved in habit formation 
[40]. The inability to maintain an appropriate balance between goal-directed behaviors and 
habitual responding is key to multiple neuropsychiatric disorders. Particularly in obsessive-
compulsive disorder where repetitive actions interfere significantly with daily functioning 
[44]. Given the lack of observed TAT-induced changes in cortical dopamine and 5-HT 
neurochemistry, it is unlikely that impairments in cortical dopamine or 5-HT function 
underlie TAT-induced facilitation of reversal learning. However, receptor expression and 
signaling may be altered. Further studies are required to determine the full extent of TAT 
exposure on cortical neurotransmission.  
One mediator of TAT-induced behavioral alterations may be altered glutamate 
function. We observed global trends toward TAT-induced increases in glutamine levels and 
the ratio of glutamine/glutamate. Excess glutamate levels result in excitotoxicity which has 
been suggested as a neuropathological mechanism associated with HIV infection[45]. In a 
healthy brain, glutamate levels are tightly regulated via astrocytic conversion to a less toxic 
alternative, glutamine. Thus, TAT-induced increases in glutamine levels may be a 
compensatory response to reduce elevated glutamate release. Combined increases in glutamate 
and glutamine levels have been observed in the cortex of patients with acute HIV infection 
[46]. Furthermore, it has recently been shown that increases in cerebrospinal fluid glutamine 
levels were associated with improvements in the cognitive status of HIV-infected subjects 
[47] supporting the premise that this may be a compensatory factor. Given that acute TAT 
has been shown to decrease glutamine and increase glutamate levels in cultured 
neuroblastoma cells [48], it may be that the observed opposite trends for increased glutamine 
levels in TAT+ mice are in response to the long-term effects of prior TAT protein expression. 
TAT protein expression in this mouse model persists for less than 14 days after doxycycline 
treatment [38]. The brain samples in the current study were collected 11-days after the final 
doxycycline injection making it likely that the TAT protein was no longer present. 
 
4.3 Effects of selegiline on reversal learning 
Although selegiline tended to increase spatial strategy use in TAT- mice and decrease 
its use in TAT+ mice during reversal learning, overall selegiline treatment had little effect on 
memory retention/recall and reversal learning. The impact of selegiline treatment on 
neurochemistry was consistent with its primary mode of action i.e. inhibition of MAO 
function [27]. MAO is required for the conversion of dopamine and 5-HT to DOPAC and 5-
HIAA, respectively. Increased levels of dopamine and 5-HT, reduced levels of DOPAC and 
5-HIAA or both were observed in all the brain regions assessed. Interestingly, selegiline 
treatment also increased glutamate levels specifically in the dopamine rich CPu but did not 
alter GABA levels in any of the brain regions assessed. Previous work has shown stimulant-
induced dopamine release to be increased after MAO inhibition [49]. However, our findings 
suggest that under the current experimental conditions, any potential increases in dopamine 
function by selegiline do not impact spatial memory retention or reversal learning. 
Furthermore, given that selegiline did not alter TAT-induced changes in reversal learning, we 
conclude that it is unlikely that altered dopamine function was a causative factor in this 
behavioral outcome.  
 
4.4 Conclusions 
Our results suggest that prior TAT protein expression in the brain of mice leads to the 
facilitation of late-phase reversal learning. This behavioral pattern is consistent with results 
observed after PFC damage [40] suggesting that TAT-induced cortical pathology may 
mediate this behavioral alteration. Furthermore, TAT-induced facilitation of reversal learning 
is unlikely to be attributed to dopamine or 5-HT function because selegiline treatment did not 
normalize TAT-induced effects or alter behavior in mice not exposed to TAT in this task. In 
conclusion, this work suggests that, in the absence of impaired learning, TAT protein does 
not impair spatial memory retention/recall but facilitates late phase reversal learning in a 
manner consistent with PFC damage. Furthermore, TAT-induced alterations in glutamate 
signaling, but not alterations in dopamine and 5-HT metabolism, may underlie TAT-induced 
changes in reversal learning.  
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 Figure Captions 
Figure 1. A graphical representation of the testing and treatment timeline.  
Figure 2. Average reference errors (A), working memory errors (B), perseverative errors (C) 
and the percentage of spatial (D), serial (E) and mixed/random (F) strategy use during days 
of retention (Ret) and reversal learning (Rv) testing in the Barnes maze test. **p<0.01, 
***p<0.001; significant main effect of TAT. #p<0.06; near significant interaction of TAT x 
Selegiline.  
Figure 3. Average Latency (A), reference errors (B), working memory (WM) errors (C) and 
the percentage of spatial strategy used (D) on the second day of reversal learning trials in the 
Barnes maze test. TAT+ mice (grey bars) took less time, and made fewer reference and 
working memory errors compared with TAT- control mice (white bars). TAT+ mice treated 
with saline (grey, non-hatched bar) utilised a spatial strategy on a greater percentage of trials 
compared with TAT- control mice treated with saline (white, non-hatched bar; D). Selegiline 
treatment tended to increase spatial strategy use in TAT- control mice and decrease spatial 
strategy use in TAT+ mice. *p<0.05, **p<0.01, ***p<0.001. 
  
Tables 
Table 1 Neurotransmitter levels in the caudate putamen 
 TAT-/Sel- TAT+/Sel- TAT-/Sel+ TAT+/Sel+ SME 
 Mean SEM Mean SEM Mean SEM Mean SEM Sel TAT 
Dopamine system           
DA 12644.2 471.1 13213.7 508.9 16027.2 458.1 15171.4 417.5 ***  
DOPAC 1564.3 80.7 1355.3 75.3 777.6 28.1 698.2 19.4 *** * 
3-MT 608.28 25.29 597.96 24.78 838.10 26.13 779.65 21.58 ***  
HVA 1013.0 37.9 1006.4 49.0 881.6 24.3 864.3 37.4 ***  
DOPAC/DA 0.1253 0.0076 0.1032 0.0053 0.0487 0.0017 0.0465 0.0019 *** * 
HVA/DA 0.0805 0.0021 0.0762 0.0024 0.0553 0.0016 0.0572 0.0024   
DOPAC/HVA 1.5644 0.0898 1.3578 0.0605 0.8841 0.0286 0.8194 0.0254 *** * 
Serotonin system           
5-HT 387.32 13.80 379.24 14.69 404.90 21.21 435.36 11.93 *  
5-HIAA 233.57 11.15 236.72 14.17 223.84 10.44 249.17 11.58   
5-HIAA/5-HT 0.6124 0.0355 0.6339 0.0436 0.5616 0.0242 0.5743 0.0239   
Amino acids           
GLU 1404.5 46.5 1397.3 53.4 1487.0 41.2 1522.4 34.4 *  
GABA 180.84 10.40 177.50 8.06 183.44 5.07 188.58 9.08   
Glutamine 1317.1 86.9 1397.5 100.0 1280.6 59.5 1533.5 116.5   
GLU/GABA 7.95 0.31 7.93 0.19 8.19 0.35 8.33 0.43   
Gln/GLU 0.9312 0.0427 0.9989 0.0582 0.8689 0.0477 0.9941 0.0561   
Sel, Selegiline; SME, significant main effects; SEM, standard error of the mean; DA, dopamine; 
DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine; HVA, homovanillic acid; 5-HT, 
serotonin; 5-HIAA, 5-hydroxy-indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, 
glutamine. *p<0.05, ***p<0.001. 
  
Table 2 Neurotransmitter levels in the hippocampus 
 TAT-/Sel- TAT+/Sel- TAT-/Sel+ TAT+/Sel+ SME 
 Mean SEM Mean SEM Mean SEM Mean SEM Sel TAT 
Dopamine system           
DA 13.31 0.88 13.91 1.10 21.55 2.01 22.06 2.67 ***  
DOPAC 17.20 0.70 17.41 0.78 11.41 0.49 11.61 0.82 ***  
3-MT 0.71 0.07 0.71 0.05 1.82 0.17 2.09 0.66 ***  
HVA 22.72 0.52 23.63 1.00 19.29 0.59 20.53 1.65 **  
DOPAC/DA 1.3707 0.0962 1.3197 0.0768 0.5661 0.0399 0.5982 0.0605 ***  
HVA/DA 1.8074 0.1100 1.8034 0.1123 0.9644 0.0692 1.0519 0.1073 ***  
DOPAC/HVA 0.7553 0.0219 0.7379 0.0182 0.5919 0.0205 0.5727 0.0187 ***  
Serotonin system           
5-HT 702.67 19.71 714.07 20.70 828.35 29.12 842.96 22.37 ***  
5-HIAA 410.20 10.85 424.11 17.63 335.72 9.67 380.45 17.05 *** * 
5-HIAA/5-HT 0.5947 0.0283 0.6085 0.0397 0.4109 0.0182 0.4574 0.0259 ***  
Amino acids           
GLU 1465.8 45.9 1434.7 19.0 1431.3 30.0 1490.9 28.2   
GABA 219.31 5.86 208.58 3.74 206.30 6.19 219.96 4.77   
Glutamine 1148.6 90.6 1208.5 84.8 1086.5 51.0 1335.3 101.8   
GLU/GABA 6.70 0.15 6.90 0.11 6.99 0.18 6.80 0.14   
Gln/GLU 0.7744 0.0378 0.8377 0.0518 0.7638 0.0419 0.8964 0.0670   
Sel, Selegiline; SME, significant main effects; SEM, standard error of the mean; DA, dopamine; 
DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine; HVA, homovanillic acid; 5-HT, 
serotonin; 5-HIAA, 5-hydroxy-indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, 
glutamine. *p<0.05, **p<0.01, ***p<0.001. 
  
Table 3 Neurotransmitter levels in the prefrontal cortex 
 TAT-/Sel- TAT+/Sel- TAT-/Sel+ TAT+/Sel+ SME 
 Mean SEM Mean SEM Mean SEM Mean SEM Sel TAT 
Dopamine system           
DA 114.67 5.51 117.04 7.39 142.23 10.60 146.42 18.23 *  
DOPAC 74.07 3.71 68.39 2.64 59.16 2.80 65.59 3.74 **  
3-MT 22.21 1.09 23.20 1.13 26.32 1.22 27.64 2.03 **  
HVA 65.48 2.88 68.11 3.40 64.71 5.08 67.37 5.59   
DOPAC/DA 0.6568 0.0325 0.6103 0.0338 0.4294 0.0204 0.4994 0.0437 ***  
HVA/DA 0.5857 0.0311 0.6042 0.0343 0.4609 0.0249 0.4928 0.0412 ***  
DOPAC/HVA 1.1434 0.0534 1.0287 0.0505 0.9539 0.0545 1.0786 0.1172   
Serotonin system           
5-HT 516.53 22.76 554.75 20.47 604.34 23.08 608.98 20.76 **  
5-HIAA 151.60 8.59 175.19 10.18 160.82 9.26 172.50 14.21   
5-HIAA/5-HT 0.2999 0.0179 0.3175 0.0175 0.2666 0.0116 0.2822 0.0205   
Amino acids           
GLU 1702.7 71.0 1775.8 55.6 1774.2 32.0 1765.8 73.4   
GABA 162.81 6.00 169.81 6.93 176.33 6.59 182.31 9.13   
Glutamine 1101.1 88.9 1219.0 91.1 1121.9 73.1 1401.5 158.5   
GLU/GABA 10.47 0.31 10.58 0.30 10.21 0.38 9.82 0.39   
Gln/GLU 0.6451 0.0378 0.6823 0.0390 0.6300 0.0345 0.7787 0.0688   
Sel, Selegiline; SME, significant main effects; SEM, standard error of the mean; DA, dopamine; 
DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine; HVA, homovanillic acid; 5-HT, 
serotonin; 5-HIAA, 5-hydroxy-indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, 




Table 4 Neurotransmitter levels in the orbitofrontal cortex 
 TAT-/Sel- TAT+/Sel- TAT-/Sel+ TAT+/Sel+ SME 
 Mean SEM Mean SEM Mean SEM Mean SEM Sel TAT 
Dopamine system           
DA 39.74 1.89 41.23 2.29 44.44 3.39 45.87 2.41   
DOPAC 36.98 1.26 38.92 2.73 33.26 1.30 31.64 1.38 **  
3-MT 2.41 0.26 2.44 0.28 4.25 0.53 4.15 0.43 ***  
HVA 52.20 3.65 63.27 6.56 51.89 5.44 54.40 5.29   
DOPAC/DA 0.9587 0.0519 0.9957 0.0953 0.7804 0.0460 0.7140 0.0451 ***  
HVA/DA 1.3422 0.0963 1.6125 0.1941 1.1625 0.0784 1.1741 0.0772 *  
DOPAC/HVA 0.7438 0.0433 0.6431 0.0281 0.7066 0.0613 0.6511 0.0646   
Serotonin system           
5-HT 509.95 16.04 553.55 18.42 584.30 19.68 606.35 18.76 ***  
5-HIAA 136.83 8.15 146.35 6.90 129.03 8.89 146.61 9.41   
5-HIAA/5-HT 0.2729 0.0193 0.2677 0.0142 0.2219 0.0144 0.2423 0.0144 *  
Amino acids           
GLU 1685.4 44.0 1657.1 43.0 1746.1 60.5 1718.2 65.3   
GABA 153.64 5.48 151.66 4.04 156.07 6.35 156.65 5.70   
Glutamine 1052.1 71.2 1126.2 93.1 1066.4 89.5 1264.6 134.3   
GLU/GABA 11.06 0.26 10.96 0.22 11.23 0.16 10.99 0.21   
Gln/GLU 0.6282 0.0431 0.6754 0.0482 0.6064 0.0377 0.7186 0.0551   
Sel, Selegiline; SME, significant main effects; SEM, standard error of the mean; DA, dopamine; 
DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine; HVA, homovanillic acid; 5-HT, 
serotonin; 5-HIAA, 5-hydroxy-indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, 
glutamine. *p<0.05, **p<0.01, ***p<0.001. 
 
